Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from the $2 million reported in the same period last year. This growth is largely attributed to the strong performance of TONMYA, its recently approved treatment for fibromyalgia, which generated approximately $11 million in net sales during the quarter. The company's commercial success is underscored by 12,592 total prescriptions for TONMYA, reflecting a 100% sequential increase, with new patient prescriptions up 36% and refills surging 207%.
The market adoption of TONMYA is further evidenced by its coverage, which currently extends to approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This figure is expected to rise to approximately 145 million lives once a managed Medicare agreement takes effect on January 1, 2027. Such broad coverage is critical for patient access and positions TONMYA as a leading option in the fibromyalgia treatment landscape.
Beyond commercial achievements, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments highlight Tonix's commitment to addressing high unmet medical needs in both CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company states that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as Tonix continues to invest in its commercial infrastructure and clinical programs.
The significance of this announcement lies in Tonix's successful transition from a development-stage company to a commercial-stage entity, with TONMYA's robust sales growth and expanding patient access. The company's ability to generate substantial revenue from its flagship product, while simultaneously advancing a diverse pipeline, positions it for sustained growth. As Tonix progresses with its pivotal studies and expands TONMYA's reach, it stands to make a meaningful impact in the treatment of fibromyalgia and other CNS and immunology conditions.
